1.7 The Future of Adaptive Trials in Clinical Drug Development
A recent study released
by the Tuft’s Center for the Study of Drug Development suggests
that the average pre-tax industry cost to bring a new medicine to
market is now around $2.56 billion USD [70]. The study included 106
investigational new drugs from 10 mid- to large-size pharmaceutical
companies and the drugs were first tested in humans during 1995-2007.
Cost included clinical development up to 2013. By comparison, in 2003,
the cost was about $1.04 billion in the 2013 dollars.
DiMasi stated that the higher cost comes from clinical trials that are larger and more complex. In our opinion, some of the higher costs also resulted from increased regulations [70]. For example, since ...
Get Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.
